Business
KRTL Holding Group Highlights Bolivian Innovation CaviGuard, Manufactured by SIGMA, as Global Model in Non-Invasive Dental Care
KRTL Holding Group Highlights Bolivian Innovation CaviGuard, Manufactured by SIGMA, as Global Model in Non-Invasive Dental Care.
About this update from Krtl Holding Group, Inc
[{"type":"text","content":"KRTL\r\nHolding Group Inc. (OTC: KRTL) (\"KRTL\" or the \"Company\") is\r\nproud to spotlight CaviGuard, an innovative dental care system developed in\r\nBolivia and manufactured by its majority-owned subsidiary, Industria\r\nQuímico-Farmacéutica SIGMA Corp. The system utilizes a non-invasive protocol\r\nthat avoids drilling and anesthesia, offering a practical alternative to\r\nconventional cavity treatment. Now expanding beyond Bolivia, CaviGuard is being\r\nintroduced in Brazil and the United States as part of broader efforts to\r\nimprove access to preventive and therapeutic dental care.\r\nCaviGuard\r\nis designed to address the global burden of untreated dental caries,\r\nparticularly in underserved and rural communities. The system eliminates the\r\nneed for drills or anesthesia, allowing for safe, comfortable, and rapid\r\ntreatment using a protocol based on silver diamine fluoride (SDF) and fluoride\r\nvarnish (FV). Developed over more than a decade, CaviGuard has been deployed in\r\nthousands of patients and validated through field trials and academic research.\r\n\"CaviGuard\r\nexemplifies the kind of scalable, community-centered innovation that aligns\r\nperfectly with KRTL's international strategy,\" said Cesar Herrera, CEO of\r\nKRTL Holding Group Inc. “Its expansion into new markets is a reflection of both\r\nits clinical value and its manufacturing quality through SIGMA.”\r\nUnlike\r\nconventional dental procedures that require drills, anesthesia, and clinical\r\ninfrastructure, CaviGuard represents a novel medical device solution tailored\r\nfor portability, cost-effectiveness, and patient comfort. By eliminating\r\ninvasive steps, it lowers barriers to care—particularly in resource-limited\r\nsettings. According to the World Health Organization, untreated dental caries\r\nis the most common health condition globally, contributing to the 3.5 billion\r\npeople affected by oral diseases. The global dental consumables market—which\r\nincludes products like fluoride varnishes and non-invasive cavity\r\ntreatments—was valued at approximately USD 36 billion in 2024, according to\r\nGrand View Research. As the licensed manufacturer, SIGMA ensures each CaviGuard\r\nunit is produced in accordance with international GMP standards, supporting\r\nquality, consistency, and alignment with global public health objectives. \r\n...